That’s potentially $80,000,000 ..jeez that’s a lot
Printable View
Dunno - its a hard one to figure out but it does look very encouraging to say the least.
One has to remember that the ones being monitored may be doing 3 or 4 tests per annum and there are roughly 80,000 new cases per annum amongst 13000 urologists. 2000 of them would get 12000 additional patients annually roughly, minus attrition for those being cured hopefully.
https://www4.bing.com/search?q=how+m...ases+of+bladde
I like everyone's optimism. Let's hope that's played out on 26th
From the HY report
Cxbladder Sales- US 4,982
HY 2021 2,906
Rounding up Sales to 5000 and dividing by 2000 urologists is 2.5 tests average each in the first 6 months of this Financial Year.
This doesn't appear to be excessive usage given that the 2000 urologists with 80000 customers have an average of 40 patients each.
Also considering that the 40 patients are "on the books" the question arises as to why are they still on the books.
Probably due to being monitored after diagnosis and treatment for any signs of recurrence.
This requires several tests per year to monitor for recurrence usually at 2 or 3 times a year or 2.5 as an average.
So given these figures it would seem that using cxBladder at that rate is equivalent to 2000 urologists using Monitor on 1 or 2 customers each.
The only fly in the ointment with this though is that they may not have had 2000 urologists signed on at the end of HY
in which case the rate of use would be higher.
There is also the Mid May conference with AUA and about 30 other conferences elsewhere to consider going forward.
Hoping for some good numbers on 26th